Financial Ratios WuXi Biologics (Cayman) Inc. OTC Markets
Stocks
WXXW.Y
US98260N1081
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.780 USD | -4.89% |
|
-11.59% | -2.75% |
| Jun. 05 | Wuxi Biologics Completes Topping Out of Drug Product Facility At Singapore Crdmo Hub | CI |
| May. 31 | Wuxi Biologics adds 69 projects in Jan-April, maintains expected revenue growth | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 5.43 | 5.81 | 4.63 | 5.05 | 6.88 | |||||
Return on Total Capital | 6.47 | 7 | 5.51 | 5.79 | 7.8 | |||||
Return On Equity % | 13.09 | 13.2 | 8.9 | 8.82 | 11.64 | |||||
Return on Common Equity | 12.82 | 13.13 | 9.02 | 8.17 | 11.02 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 46.93 | 44.04 | 40.08 | 40.97 | 45.98 | |||||
SG&A Margin | 9.72 | 9.38 | 10.5 | 11.5 | 10.62 | |||||
EBITDA Margin % | 35.2 | 33.2 | 28.93 | 31.32 | 36.37 | |||||
EBITA Margin % | 31.27 | 28.86 | 23.45 | 24.87 | 30.75 | |||||
EBIT Margin % | 30.81 | 28.49 | 23.09 | 24.55 | 30.5 | |||||
Income From Continuing Operations Margin % | 34.1 | 29.8 | 20.96 | 21.13 | 26.31 | |||||
Net Income Margin % | 32.93 | 28.95 | 19.96 | 17.97 | 22.53 | |||||
Net Avail. For Common Margin % | 32.93 | 28.95 | 19.96 | 17.97 | 22.53 | |||||
Normalized Net Income Margin | 19.04 | 19.53 | 14.26 | 13.33 | 15.85 | |||||
Levered Free Cash Flow Margin | -36.16 | -3.89 | -1.88 | -12.3 | 19.66 | |||||
Unlevered Free Cash Flow Margin | -35.92 | -3.63 | -1.3 | -11.77 | 20.07 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.28 | 0.33 | 0.32 | 0.33 | 0.36 | |||||
Fixed Assets Turnover | 0.63 | 0.67 | 0.61 | 0.64 | 0.75 | |||||
Receivables Turnover (Average Receivables) | 3.65 | 3.62 | 3 | 3.13 | 3.22 | |||||
Inventory Turnover (Average Inventory) | 3.94 | 4.31 | 5.04 | 6.71 | 8.11 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.37 | 1.98 | 2.78 | 2.73 | 3.39 | |||||
Quick Ratio | 1.85 | 1.55 | 2.35 | 1.98 | 2.96 | |||||
Operating Cash Flow to Current Liabilities | 0.42 | 0.59 | 0.61 | 0.61 | 0.76 | |||||
Days Sales Outstanding (Average Receivables) | 100.09 | 100.78 | 121.52 | 116.79 | 113.35 | |||||
Days Outstanding Inventory (Average Inventory) | 92.62 | 84.76 | 72.36 | 54.57 | 45.01 | |||||
Average Days Payable Outstanding | 38.03 | 28.2 | 49.71 | 26.83 | 28.85 | |||||
Cash Conversion Cycle (Average Days) | 154.68 | 157.33 | 144.17 | 144.54 | 129.51 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 13.13 | 12.21 | 10.36 | 10.86 | 5.85 | |||||
Total Debt / Total Capital | 11.61 | 10.88 | 9.39 | 9.8 | 5.53 | |||||
LT Debt/Equity | 6.33 | 8.15 | 8.7 | 5.1 | 3.49 | |||||
Long-Term Debt / Total Capital | 5.59 | 7.26 | 7.88 | 4.6 | 3.29 | |||||
Total Liabilities / Total Assets | 25.72 | 26.94 | 22.2 | 20.18 | 16.73 | |||||
EBIT / Interest Expense | 80.89 | 67.57 | 24.81 | 29.1 | 46.46 | |||||
EBITDA / Interest Expense | 93.18 | 80 | 32.19 | 38.22 | 56.58 | |||||
(EBITDA - Capex) / Interest Expense | -72.87 | -11.15 | 6.67 | 13.28 | 30.83 | |||||
Total Debt / EBITDA | 1.18 | 0.86 | 0.89 | 0.82 | 0.38 | |||||
Net Debt / EBITDA | -1.87 | -0.83 | -1.31 | -0.96 | -1.56 | |||||
Total Debt / (EBITDA - Capex) | -1.5 | -6.16 | 4.32 | 2.36 | 0.7 | |||||
Net Debt / (EBITDA - Capex) | 2.39 | 5.98 | -6.32 | -2.76 | -2.86 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 83.35 | 48.38 | 11.56 | 9.63 | 16.68 | |||||
Gross Profit, 1 Yr. Growth % | 90.64 | 39.25 | 1.54 | 12.05 | 30.95 | |||||
EBITDA, 1 Yr. Growth % | 104.51 | 39.93 | -2.77 | 18.68 | 35.49 | |||||
EBITA, 1 Yr. Growth % | 109.71 | 36.97 | -9.38 | 16.3 | 44.25 | |||||
EBIT, 1 Yr. Growth % | 111.01 | 37.23 | -9.6 | 16.6 | 44.95 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 107.28 | 29.68 | -21.52 | 10.5 | 45.32 | |||||
Net Income, 1 Yr. Growth % | 100.63 | 30.45 | -23.09 | -1.28 | 46.25 | |||||
Normalized Net Income, 1 Yr. Growth % | 97.42 | 52.16 | -18.54 | 1.09 | 38.75 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 92.5 | 31.17 | -23.5 | 1.55 | 47.92 | |||||
Accounts Receivable, 1 Yr. Growth % | 38.07 | 57.6 | 19.89 | -7.27 | 36.01 | |||||
Inventory, 1 Yr. Growth % | 55.63 | 35.18 | -22.59 | -13.82 | -9.23 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 53.5 | 31.18 | 15.52 | -5.02 | 4.64 | |||||
Total Assets, 1 Yr. Growth % | 52.03 | 12.56 | 14.15 | 0.71 | 11.79 | |||||
Tangible Book Value, 1 Yr. Growth % | 50.84 | 9.36 | 16.14 | 4.07 | 13.56 | |||||
Common Equity, 1 Yr. Growth % | 56.96 | 8.58 | 15.08 | 3.69 | 12.98 | |||||
Cash From Operations, 1 Yr. Growth % | 82.39 | 61.51 | -15.77 | 11.77 | 21.54 | |||||
Capital Expenditures, 1 Yr. Growth % | 8.02 | -9.83 | -31.06 | -2.87 | -6.22 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -37.79 | -84.02 | -46.11 | 616.87 | -286.57 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -37.93 | -85.01 | -60.07 | 893.3 | -299 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 60.72 | 64.94 | 28.66 | 10.59 | 13.1 | |||||
Gross Profit, 2 Yr. CAGR % | 70.62 | 62.93 | 18.91 | 6.67 | 21.13 | |||||
EBITDA, 2 Yr. CAGR % | 78.15 | 69.17 | 16.64 | 7.42 | 26.81 | |||||
EBITA, 2 Yr. CAGR % | 82.25 | 69.48 | 11.41 | 2.66 | 29.52 | |||||
EBIT, 2 Yr. CAGR % | 82.87 | 70.17 | 11.38 | 2.67 | 30 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 86.35 | 63.95 | 0.88 | -6.88 | 26.71 | |||||
Net Income, 2 Yr. CAGR % | 82.82 | 61.78 | 0.17 | -12.87 | 20.16 | |||||
Normalized Net Income, 2 Yr. CAGR % | 66.68 | 73.32 | 11.33 | -8.63 | 18.43 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 75.5 | 58.9 | 0.17 | -11.86 | 22.56 | |||||
Accounts Receivable, 2 Yr. CAGR % | 54.18 | 47.51 | 37.46 | 5.44 | 12.3 | |||||
Inventory, 2 Yr. CAGR % | 105.55 | 45.04 | 2.3 | -18.32 | -11.56 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 70.49 | 41.9 | 23.1 | 4.75 | -0.31 | |||||
Total Assets, 2 Yr. CAGR % | 58.16 | 30.82 | 13.35 | 7.22 | 6.11 | |||||
Tangible Book Value, 2 Yr. CAGR % | 57.31 | 28.43 | 12.7 | 9.94 | 8.71 | |||||
Common Equity, 2 Yr. CAGR % | 58.9 | 30.55 | 11.78 | 9.23 | 8.24 | |||||
Cash From Operations, 2 Yr. CAGR % | 68.53 | 71.63 | 16.63 | -2.97 | 16.55 | |||||
Capital Expenditures, 2 Yr. CAGR % | 42.37 | -1.31 | -21.16 | -18.17 | -4.56 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 23.49 | -68.47 | -70.66 | 96.55 | 265.72 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 23.39 | -69.49 | -75.53 | 99.14 | 344.6 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 59.53 | 56.5 | 44.79 | 21.98 | 12.59 | |||||
Gross Profit, 3 Yr. CAGR % | 68.04 | 59.45 | 39.17 | 16.58 | 14.22 | |||||
EBITDA, 3 Yr. CAGR % | 76.05 | 64.37 | 40.65 | 17.32 | 16.06 | |||||
EBITA, 3 Yr. CAGR % | 82.16 | 65.7 | 37.56 | 13.02 | 14.99 | |||||
EBIT, 3 Yr. CAGR % | 82.4 | 66.18 | 37.82 | 13.09 | 15.18 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 77.21 | 65.14 | 28.25 | 3.99 | 8.01 | |||||
Net Income, 3 Yr. CAGR % | 75.15 | 63.37 | 26.26 | -0.32 | 3.55 | |||||
Normalized Net Income, 3 Yr. CAGR % | 62.03 | 61.69 | 34.76 | 8.3 | 5.02 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 68.83 | 59.27 | 24.54 | 0.63 | 4.74 | |||||
Accounts Receivable, 3 Yr. CAGR % | 60.01 | 55.31 | 37.66 | 20.55 | 14.78 | |||||
Inventory, 3 Yr. CAGR % | 95.11 | 78.75 | 17.65 | -3.39 | -15.4 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 89.48 | 56.23 | 32.5 | 12.91 | 4.71 | |||||
Total Assets, 3 Yr. CAGR % | 67.36 | 41.21 | 25 | 8.97 | 8.72 | |||||
Tangible Book Value, 3 Yr. CAGR % | 57.87 | 39.35 | 24.2 | 9.74 | 11.13 | |||||
Common Equity, 3 Yr. CAGR % | 59.24 | 39.96 | 25.17 | 9.02 | 10.47 | |||||
Cash From Operations, 3 Yr. CAGR % | 65.16 | 66.16 | 35.38 | 14.99 | 4.59 | |||||
Capital Expenditures, 3 Yr. CAGR % | 69.32 | 22.27 | -12.43 | -15.48 | -14.37 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 44.25 | -37.54 | -62.31 | -14.86 | 93.16 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 43.94 | -38.88 | -66.63 | -15.91 | 99.1 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 59.75 | 56.65 | 46.38 | 36.21 | 31.17 | |||||
Gross Profit, 5 Yr. CAGR % | 65.48 | 59.05 | 46.33 | 35.76 | 31.65 | |||||
EBITDA, 5 Yr. CAGR % | 62.56 | 59.04 | 49.32 | 38.65 | 34.94 | |||||
EBITA, 5 Yr. CAGR % | 70.11 | 60.74 | 49.64 | 36.82 | 34.29 | |||||
EBIT, 5 Yr. CAGR % | 69.6 | 60.32 | 49.74 | 37.06 | 34.64 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 90.16 | 78.28 | 41.45 | 31.32 | 27.63 | |||||
Net Income, 5 Yr. CAGR % | 88.84 | 77.25 | 40.07 | 27.05 | 23.78 | |||||
Normalized Net Income, 5 Yr. CAGR % | 77.92 | 74.27 | 39.45 | 28.69 | 28.32 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 73.63 | 68.98 | 37.02 | 25.7 | 23.75 | |||||
Accounts Receivable, 5 Yr. CAGR % | 61.94 | 75 | 50.58 | 33.02 | 26.9 | |||||
Inventory, 5 Yr. CAGR % | 52.93 | 46.51 | 50.7 | 30.67 | 4.96 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 76.52 | 70.85 | 59.46 | 33.14 | 18.25 | |||||
Total Assets, 5 Yr. CAGR % | 85.87 | 59.19 | 43.21 | 26.48 | 17.07 | |||||
Tangible Book Value, 5 Yr. CAGR % | 156.7 | 52.29 | 37.96 | 26.74 | 17.75 | |||||
Common Equity, 5 Yr. CAGR % | 160.23 | 54.17 | 38.22 | 26.75 | 18.1 | |||||
Cash From Operations, 5 Yr. CAGR % | 111.06 | 72.74 | 43.71 | 33.99 | 27.51 | |||||
Capital Expenditures, 5 Yr. CAGR % | 72.27 | 54.32 | 24.72 | 4.12 | -9.36 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 46.1 | 9.22 | -23.71 | -1.2 | -6.46 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 46.71 | 9 | -29.15 | -1.97 | -5.98 |
Select your edition
All financial news and data tailored to specific country editions
















